U.S. markets closed

Precigen, Inc. (PGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.54-0.10 (-1.51%)
At close: 4:00PM EDT

6.45 -0.09 (-1.38%)
After hours: 5:48PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close6.64
Open6.72
Bid6.45 x 3200
Ask6.61 x 1800
Day's Range6.37 - 6.80
52 Week Range2.14 - 11.10
Volume1,375,783
Avg. Volume1,299,206
Market Cap1.35B
Beta (5Y Monthly)2.33
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 07, 2021 - May 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Precigen, Inc. (PGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zacks

    Precigen, Inc. (PGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Precigen Announces Departure of Chief Financial Officer
    PR Newswire

    Precigen Announces Departure of Chief Financial Officer

    Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that by mutual agreement Rick Sterling is stepping down from his position as Chief Financial Officer effective April 2, 2021. Precigen has commenced an executive search for a successor with the qualifications to contribute to Precigen's accelerating growth from a clinical stage company to a commercial organization.

  • How Much Of Precigen, Inc. (NASDAQ:PGEN) Do Insiders Own?
    Simply Wall St.

    How Much Of Precigen, Inc. (NASDAQ:PGEN) Do Insiders Own?

    Every investor in Precigen, Inc. ( NASDAQ:PGEN ) should be aware of the most powerful shareholder groups. Institutions...